{"id":"extra-fine-formoterol-beclomethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Hoarseness"}]},"_chembl":{"chemblId":"CHEMBL1586","moleculeType":"Small molecule","molecularWeight":"408.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Formoterol acts as a bronchodilator by stimulating beta-2 adrenergic receptors on airway smooth muscle, causing relaxation and airway opening. Beclomethasone is a corticosteroid that suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production, edema, and eosinophil infiltration. The extra-fine particle formulation enhances deposition in small airways.","oneSentence":"This combination inhaler delivers a long-acting beta-2 agonist (formoterol) to relax airway smooth muscle and an inhaled corticosteroid (beclomethasone) to reduce airway inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:32.820Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT07406048","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Farmaceutica Ltda.","startDate":"2026-01-30","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":396},{"nctId":"NCT06567977","phase":"","title":"TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients","status":"RECRUITING","sponsor":"Chiesi Poland Sp. z o.o.","startDate":"2024-08","conditions":"Asthma","enrollment":60},{"nctId":"NCT05728749","phase":"","title":"A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes","status":"UNKNOWN","sponsor":"Chiesi SAS","startDate":"2023-03-03","conditions":"ASTHMA","enrollment":300},{"nctId":"NCT04876677","phase":"PHASE3","title":"Functional Respiratory Imaging Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-05-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT04421742","phase":"","title":"The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.","status":"COMPLETED","sponsor":"Alfredo Antonio Chetta","startDate":"2017-05-31","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":43},{"nctId":"NCT01650441","phase":"PHASE2","title":"Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2012-04","conditions":"Asthma","enrollment":31},{"nctId":"NCT02345993","phase":"PHASE4","title":"Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis","status":"UNKNOWN","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2015-01","conditions":"Asthma, Asthmatic Crisis","enrollment":120},{"nctId":"NCT01453881","phase":"PHASE3","title":"Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation","status":"COMPLETED","sponsor":"Universidade Federal de Pernambuco","startDate":"2011-04","conditions":"Asthma","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Innovair"],"phase":"marketed","status":"active","brandName":"Extra fine Formoterol/Beclomethasone","genericName":"Extra fine Formoterol/Beclomethasone","companyName":"National Institute of Respiratory Diseases, Mexico","companyId":"national-institute-of-respiratory-diseases-mexico","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhaler delivers a long-acting beta-2 agonist (formoterol) to relax airway smooth muscle and an inhaled corticosteroid (beclomethasone) to reduce airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}